Published on
The results of the study could help to identify patients with AML who do not respond well to chemotherapy and may instead benefit from novel immunotherapy.
Published on
The $200,000 award will fund research to develop a novel therapeutic that ignites the immune system and could act as a stand-alone treatment, as well as boost the effectiveness of existing immunotherapies.
Published on
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
Published on
A new multicenter study led by researchers at CHOP as part of the Children’s Oncology Group found that pediatric AML patients who had the antifungal prophylaxis with caspofungin had significantly fewer cases of invasive fungal disease compared with those who had fluconazole.
Published on
The $220,000 award will be directed to a Phase I clinical trial that will investigate the effectiveness of CAR T-cell therapy to treat AML.
Published on
Dr. Richard Aplenc has received a $1 million Hyundai Quantum Grant from Hyundai Hope on Wheels to advance treatment for a high-risk form of childhood leukemia
Published on
After children with leukemia receive chemotherapy, are they better off remaining in the hospital, or going home? CHOP is leading a multicenter study of both safety and family preferences.
Published on
The history of our understanding and approach to cancer are at the center of CANCER: THE EMPEROR OF ALL MALADIES. The documentary will air in three parts on March 30, 31 and April 1 at 9 p.m. ET on PBS, with the final chapter featuring CHOP.
Published on
Beverly Lange, MD, a retired oncologist from The Children's Hospital of Philadelphia, was recognized for her lifetime of work with pediatric leukemia patients.
Published on
CHOP researchers say changing patients’ skin cells into stem cells shows great promise in investigating and eventually treating a childhood leukemia and Diamond-Blackfan anemia.